Multiple myeloma in the African American population: A 2010-2020 NCDB analysis.

e19531 Background: Multiple myeloma (MM) exhibits a disproportionately higher prevalence among African American individuals. Various factors contribute to the disease's progression, severity, and prognosis. This analysis presents real-world data from the National Cancer Database (NCDB) from 2010 to 2020. Methods: Cohort of 241, 446 MM patients between 2010 and 2020 were analyzed. Demographic variations, including age, gender, insurance status, educational attainment, and median household income, were examined. Multivariate Cox regression analysis was conducted to identify factors influencing survival outcomes. Results: Within the database, from 2010 to 2020, 51, 668 cases of multiple myeloma were recorded among Black individuals. The age group most affected was 40 to 65 years (50. 2%), followed by those over 65 (47. 3%), with 2. 5% falling between 18 to 40 years, and a mean age of 64. 4 years. Most cases affected females (51. 5%), with most households earning less than 40, 227 annually. A significant portion of Black patients did not receive a transplant (83. 8%) or immune based option (73. 1%). The mean duration from diagnosis to therapy initiation was 37. 5 days. Multivariate analysis revealed that patients over 65 had a worse prognosis (HR = 1. 52, 95% CI: 1. 47 – 1. 57, P < 0. 001) compared to those under 65, while females exhibited a better prognosis (HR = 0. 88, 95% CI: 0. 86 – 0. 91, P < 0. 001). Patients with private insurance had better outcomes (HR = 0. 73, 95% CI: 0. 68 – 0. 78, P < 0. 001), as did those treated in academic centers (HR = 0. 89, 95% CI: 0. 87 – 0. 92, P < 0. 001). Additionally, patients receiving any form of transplant had better outcomes (HR = 0. 45, 95% CI: 0. 42 - 0. 49, P < 0. 001), along with those undergoing chemotherapy (HR = 0. 73, 95% CI: 0. 68 – 0. 78, P < 0. 001) and immunotherapy (HR = 0. 67, 95% CI: 0. 64 – 0. 69, P < 0. 001). Conclusions: The analysis highlights significant demographic and treatment influences among African American patients with MM. Some identifiable factors associated with improved outcomes include younger age, female gender, private insurance, treatment in academic centers, and most importantly receipt of transplant and Immunotherapy. These findings underscore the importance of targeted interventions considering various factors and improving outcomes in this population. Table: see text